Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO

被引：1

作者：

Pauligk, Claudia

Tannapfel, Andrea

Meiler, Johannes

Luley, Kim Barbara

Kopp, Hans-Georg

Homann, Nils

Hofheinz, Ralf Dieter

Schmalenberg, Harald

Probst, Stephan

Haag, Georg Martin

Egger, Matthias

Behringer, Dirk M.

Stoehlmacher, Jan

Prasnikar, Nicole

Block, Andreas

Trojan, Jorg

Koenigsmann, Michael

Schmiegel, Wolff

Jaeger, Elke

Al-Batran, Salah-Eddin

机构：

[1] Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany

[2] Ruhr Univ Bochum, Inst Pathol, Bochum, Germany

[3] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany

[4] UKSH Campus Luebeck, Lubeck, Germany

[5] Univ Hosp, Med Ctr 2, Tubingen, Germany

[6] Acad Teaching Hosp Wolfsburg, Dept Internal Med 2, Wolfsburg, Germany

[7] Univ Med Ctr Mannheim, Dept Hematol & Med Oncol, Mannheim, Germany

[8] Univ Klinikum Jena, Jena, Germany

[9] Klinikum Bielefeld, Bielefeld, Germany

[10] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany

[11] Ortenau Klinikum Lahr, Lahr, Germany

[12] Augusta Kranken Anstalt, Bochum, Germany

[13] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[14] Klinikum Ludwigsburg, Ludwigsburg, Germany

[15] Univ Hosp Hamburg Eppendorf, Hamburg, Germany

[16] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany

[17] MediProjekt, Hannover, Germany

[18] Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Internal Med, Bochum, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.4016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4016

引用

页数：1

共 50 条

[31] A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Kim, Jin Won
Suh, Koung Jin
Kim, Ji-Won
Park, Jin Hyun
Kim, Ki Hwan
Kim, Yu Jung
Kim, Jin-Soo
Kim, Jee Hyun
Choi, In Sil
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[32] Efficacy, safety and health-related quality of life with epirubicin, cisplatin plus 5-FU (ECF) and docetaxel, cisplatin plus 5-FU (DCF) regimens as first-line systemic chemotherapy in metastatic gastric cancer: Final results of a phase II study
Chaudhuri, T.
Babu, K. G.
Lakshmaiah, K. C.
Dasappa, L.
Jacob, L. A.
Babu, M. C. S.
Rudresha, A. H.
Lokesh, K. N.
Rajeev, L. K.
ANNALS OF ONCOLOGY, 2017, 28
[33] Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer
Bae, Woo Kyun
Hwang, Jun Eul
Shim, Hyun Jeong
Cho, Sang Hee
Lee, Joon Kyoo
Lim, Sang-Chul
Chung, Woong-Ki
Chung, Ik-Joo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) : 589 - 595
[34] Phase II study of docetaxel, cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy for advanced nasopharyngeal cancer
Cho, S.
Bae, W.
Hwang, J.
Shim, H.
Lee, J.
Lim, S.
Chung, W.
Chung, I.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[35] Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer
Woo Kyun Bae
Jun Eul Hwang
Hyun Jeong Shim
Sang Hee Cho
Joon Kyoo Lee
Sang-Chul Lim
Woong-Ki Chung
Ik-Joo Chung
Cancer Chemotherapy and Pharmacology, 2010, 65 : 589 - 595
[36] A comparative study of the response and toxicities in locally advanced head and neck cancer patients treated with paclitaxel, cisplatinum, 5-FU versus docetaxel, cisplatinum, 5-FU as neoadjuvant chemotherapy followed by concurrent chemoradiation.
Samanta, Diptirani
Senapati, Surendra Nath
Mohanty, Kirti Ranjan
Das, Saroj
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[37] Efficacy and safety of perioperative FLOT (5-FU, LV, oxaliplatin, docetaxel) chemotherapy in gastric and gastroesophageal junction adenocarcinoma: Real-life data from Turkish oncology group
Erol, C.
Basoglu, T.
Sakin, A.
Ozden, E.
Cubuk, D.
Yumuk, P. F.
Dogan, M.
Oksuzoglu, B.
Yildirim, H. C.
Oner, I.
Eryilmaz, M. Karakurt
Dulgar, O.
Bekmez, E. Turkmen
Dogan, N.
Ozen, M.
Gurler, F.
Paksoy, N.
Aksoy, A.
Hizal, M.
Sendur, M. A. N.
ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
[38] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Al-Batran, Salah-Eddin
Homann, Nils
Pauligk, Claudia
Goetze, Thorsten O.
Meiler, Johannes
Kasper, Stefan
Kopp, Hans-Georg
Mayer, Frank
Haag, Georg Martin
Luley, Kim
Lindig, Udo
Schmiegel, Wolff
Pohl, Michael
Stoehlmacher, Jan
Folprecht, Gunnar
Probst, Stephan
Prasnikar, Nicole
Fischbach, Wolfgang
Mahlberg, Rolf
Trojan, Joerg
Koenigsmann, Michael
Martens, Uwe M.
Thuss-Patience, Peter
Egger, Matthias
Block, Andreas
Heinemann, Volker
Illerhaus, Gerald
Moehler, Markus
Schenk, Michael
Kullmann, Frank
Behringer, Dirk M.
Heike, Michael
Pink, Daniel
Teschendorf, Christian
Loehr, Carmen
Bernhard, Helga
Schuch, Gunter
Rethwisch, Volker
von Weikersthal, Ludwig Fischer
Hartmann, Joerg T.
Kneba, Michael
Daum, Severin
Schulmann, Karsten
Weniger, Joerg
Belle, Sebastian
Gaiser, Timo
Oduncu, Fuat S.
Guentner, Martina
Hozaeel, Wael
Reichart, Alexander
LANCET, 2019, 393 (10184): : 1948 - 1957
[39] Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
Chon, Hong Jae
Rha, Sun Young
Im, Chong Kun
Kim, Chan
Hong, Min Hee
Kim, Hye Ryun
An, Jung Ryun
Noh, Sung Hoon
Chung, Hyun Cheol
Jeung, Hei-Cheul
CANCER RESEARCH AND TREATMENT, 2009, 41 (04): : 196 - 204
[40] Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer
Bleiberg, H
Conroy, T
Paillot, B
Lacave, AJ
Blijham, G
Jacob, JH
Bedenne, L
Namer, M
DeBesi, P
Gay, F
Collette, L
Sahmoud, T
EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) : 1216 - 1220

← 1 2 3 4 5 →